ArticleEmerging infectious diseases2023
COVID-19 Epidemiology during Delta Variant Dominance Period in 45 High-Income Countries, 2020-2021.
Article in Emerging infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Impact of timely vaccination and genomic surveillance on controlling consecutive waves of SARS-CoV-2 variants.Scientific reports · 2026Article
- Epidemiological Trends of COVID-19 Infection and Symptom Incidence in China Following the Adjustment of Zero-COVID Policy: A Prospective, Community-Based Cohort Study.Transboundary and emerging diseases · 2026Article
- Vaccination-driven evolution of infectious bronchitis virus in Korea: implication for the control of other coronavirus infections.Frontiers in veterinary science · 2026Review
- Diversity and clinical correlations of SARS-CoV-2 variant during the introduction of the Delta variant in Guatemala.Access microbiology · 2026Article
- Article
- Who is American? A comprehensive analysis of the American = White/Foreign = Asian stereotype (2007-2023).Scientific reports · 2025Article
- Outpatient pediatric care during the COVID-19 pandemic, Almaty, Kazakhstan 2021-2022.Frontiers in public health · 2025Article
- Unveiling pandemic patterns: a detailed analysis of transmission and severity parameters across four COVID-19 waves in Bogotá, Colombia.BMC global and public health · 2024Article
- Risk factors for mortality in hospitalized COVID-19 patients across five waves in Pakistan.Scientific reports · 2024Article
- Emergence of SARS-CoV-2 variants KP.2 and KP.3 sparks concerns: What should we do?Health care science · 2024Article
- Precision public health in the era of genomics and big data.Nature medicine · 2024Review
- Country-specific determinants for COVID-19 case fatality rate and response strategies from a global perspective: an interpretable machine learning framework.Population health metrics · 2024Article
- Trends in mortality risk of patients with congenital heart disease during the COVID-19 pandemic.American heart journal · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The SARS-CoV-2 Delta variant, first identified in October 2020, quickly became the dominant variant worldwide. We used publicly available data to explore the relationship between illness and death (peak case rates, death rates, case-fatality rates) and selected predictors (percentage vaccinated, percentage of the population >65 years, population density, testing volume, index of mitigation policies) in 45 high-income countries during the Delta wave using rank-order correlation and ordinal regression. During the Delta-dominant period, most countries reported higher peak case rates (57%) and lower peak case-fatality rates (98%). Higher vaccination coverage was protective against peak case rates (odds ratio 0.95, 95% CI 0.91-0.99) and against peak death rates (odds ratio 0.96, 95% CI 0.91-0.99). Vaccination coverage was vital to preventing infection and death from COVID-19 during the Delta wave. As new variants emerge, public health authorities should encourage the uptake of COVID-19 vaccination and boosters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.